Last reviewed · How we verify
Omeprazole, Amoxicillin, Metronidazole and Clarithromycin
This is a quadruple therapy combination that eradicates Helicobacter pylori by suppressing gastric acid while simultaneously attacking the bacteria with three different antibiotics.
This is a quadruple therapy combination that eradicates Helicobacter pylori by suppressing gastric acid while simultaneously attacking the bacteria with three different antibiotics. Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated chronic gastritis.
At a glance
| Generic name | Omeprazole, Amoxicillin, Metronidazole and Clarithromycin |
|---|---|
| Also known as | Quadruple therapy group |
| Sponsor | Al-Azhar University |
| Drug class | Proton pump inhibitor + antibiotic combination therapy |
| Target | H+ ATPase (omeprazole); bacterial ribosome and cell wall (amoxicillin, clarithromycin); bacterial DNA (metronidazole) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Omeprazole is a proton pump inhibitor that reduces gastric acid secretion, creating an environment where the three antibiotics—amoxicillin, metronidazole, and clarithromycin—can effectively penetrate and kill H. pylori. Amoxicillin and clarithromycin inhibit bacterial protein synthesis and cell wall formation, while metronidazole generates reactive oxygen species that damage bacterial DNA. This multi-pronged approach significantly increases eradication rates compared to dual or triple therapy.
Approved indications
- Helicobacter pylori infection eradication in peptic ulcer disease
- H. pylori-associated chronic gastritis
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Headache
- Taste disturbance (metallic taste from metronidazole)
- Allergic reactions (amoxicillin)
Key clinical trials
- Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis (PHASE4)
- Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans (PHASE3)
- Comparison of Two Treatment Regimens of Helicobacter Pylori Infection (PHASE4)
- A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children (NA)
- Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication (PHASE4)
- Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians (PHASE4)
- Feasibility Study of the Proposed Test-and-treat Screening Program in Younger Participants With H. Pylori Infection
- The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: